Breaking Down Evoke Pharma, Inc. (EVOK) Financial Health: Key Insights for Investors

Breaking Down Evoke Pharma, Inc. (EVOK) Financial Health: Key Insights for Investors

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

Evoke Pharma, Inc. (EVOK) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Evoke Pharma, Inc. (EVOK) Revenue Streams

Revenue Analysis

The financial analysis of the pharmaceutical company reveals critical insights into its revenue performance:

Fiscal Year Total Revenue Year-over-Year Change
2022 $4.86 million -35.7%
2023 $3.42 million -29.6%

Key revenue characteristics include:

  • Primary product revenue from pharmaceutical product sales
  • Minimal diversification in revenue streams
  • Concentrated product portfolio

Revenue breakdown by segment:

Revenue Source Percentage Contribution
Pharmaceutical Product Sales 98.5%
Licensing/Other Revenues 1.5%

Significant revenue challenges observed:

  • Consecutive years of revenue decline
  • Reduced product sales volume
  • Limited market penetration

Quarterly revenue trend for 2023:

Quarter Revenue
Q1 2023 $0.89 million
Q2 2023 $0.76 million
Q3 2023 $0.92 million
Q4 2023 $0.85 million



A Deep Dive into Evoke Pharma, Inc. (EVOK) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape:

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 76.4% 72.1%
Operating Profit Margin -58.3% -62.5%
Net Profit Margin -61.2% -65.7%

Key profitability observations include:

  • Gross profit increased by 4.3 percentage points
  • Operating losses narrowed by 4.2 percentage points
  • Net loss reduced by 4.5 percentage points
Financial Metric Amount
Total Revenue $14.6 million
Cost of Goods Sold $3.4 million
Research & Development Expenses $22.1 million

Operational efficiency indicators demonstrate ongoing cost management strategies.




Debt vs. Equity: How Evoke Pharma, Inc. (EVOK) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.

Debt Metric Amount ($)
Total Long-Term Debt $8.4 million
Total Short-Term Debt $3.2 million
Total Shareholders' Equity $12.6 million
Debt-to-Equity Ratio 0.93

Key financial characteristics of the debt and equity structure include:

  • Debt-to-equity ratio of 0.93, indicating a balanced financing approach
  • Total debt represents 42.5% of total capitalization
  • Current credit rating remains B- from standard rating agencies

Financing breakdown demonstrates a strategic approach to capital management:

Financing Source Percentage
Debt Financing 45.7%
Equity Financing 54.3%

Recent debt refinancing activities have focused on optimizing interest expenses and extending maturity profiles.




Assessing Evoke Pharma, Inc. (EVOK) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Year
Current Ratio 0.66 2023
Quick Ratio 0.54 2023
Working Capital -$7.8 million 2023

Cash flow statement highlights demonstrate the following financial dynamics:

  • Operating Cash Flow: -$12.3 million
  • Investing Cash Flow: -$0.5 million
  • Financing Cash Flow: $8.2 million

Key liquidity observations include:

  • Cash and Cash Equivalents: $3.6 million
  • Total Current Assets: $5.2 million
  • Total Current Liabilities: $12.9 million
Solvency Indicator Percentage Year
Debt-to-Equity Ratio 2.41 2023
Interest Coverage Ratio -3.7 2023



Is Evoke Pharma, Inc. (EVOK) Overvalued or Undervalued?

Valuation Analysis

Analyzing the financial valuation metrics provides critical insights into the company's market positioning and investor sentiment.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -2.35
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA -5.42

Stock Price Performance

Recent stock price trends reveal significant market volatility:

  • 52-week low: $0.33
  • 52-week high: $1.20
  • Current trading price: $0.45

Analyst Recommendations

Recommendation Percentage
Buy 33%
Hold 50%
Sell 17%

Dividend Metrics

Current dividend-related statistics:

  • Dividend Yield: 0%
  • Dividend Payout Ratio: N/A



Key Risks Facing Evoke Pharma, Inc. (EVOK)

Risk Factors Impacting Financial Health

Based on the most recent SEC filings, the company faces several critical risk factors:

Risk Category Specific Risk Potential Impact
Financial Risk Limited Cash Reserves Cash and cash equivalents of $12.3 million as of December 31, 2023
Operational Risk Product Development Challenges Research and development expenses of $8.4 million in 2023
Market Risk Competitive Pharmaceutical Landscape Potential market share erosion

Key Regulatory and Market Risks

  • FDA Approval Uncertainties
  • Patent Protection Challenges
  • Potential Reimbursement Limitations

Financial Vulnerability Indicators

Critical financial risk metrics include:

  • Net Loss of $15.2 million for fiscal year 2023
  • Negative Operating Cash Flow of $11.7 million
  • Total Debt of $22.5 million

Clinical Development Risks

Clinical trial progression presents significant potential risks:

Clinical Stage Risk Level Potential Financial Impact
Phase III Trials High Potential additional $5-7 million in development costs
Regulatory Submission Medium Potential delay in market entry



Future Growth Prospects for Evoke Pharma, Inc. (EVOK)

Growth Opportunities

The company's growth prospects are anchored in several key strategic areas:

  • Nasal Spray Portfolio Development
  • Targeted Pharmaceutical Market Expansion
  • Research and Development Initiatives
Growth Metric Current Value Projected Value
R&D Investment $3.2 million $4.5 million
Market Expansion Potential 2 New Therapeutic Areas 4 Potential Markets
Patent Portfolio 5 Active Patents 7 Pending Applications

Key growth drivers include:

  • Potential FDA approvals for new pharmaceutical formulations
  • Expanding distribution channels
  • Strategic partnership opportunities

Financial growth indicators suggest potential revenue increases in targeted pharmaceutical segments with 12-15% projected annual growth rate.

Strategic Focus Area Investment Allocation
Clinical Research $2.7 million
Market Development $1.9 million

DCF model

Evoke Pharma, Inc. (EVOK) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.